Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Prudential announces new share buybacks as H1 profits beat estimates

(Sharecast News) - Prudential delivered double-digit growth across its key metrics in the first half, with earnings coming in ahead of analysts' forecasts as it announced new plans for share buybacks over the next two years. The company, which said it had reached an "inflection point in our capital generation", said it would repurchase $500m of shares in 2026 and $600m in 2027.

Including the existing $2bn share buyback programme, the insurance and asset management company expects to have returned more than $5bn to shareholders over 2024 to 2027 in total.

New business profit over the six months to 30 June was up 12% at $1.26bn, while operating free surplus generated from in-force insurance and asset management business rose 14% to $1.56bn. Meanwhile, adjusted operating profit before tax was 6% higher than last year at $1.64bn, beating the $1.63bn consensus forecast.

The company raised its first interim dividend by 13% to 7.71 cents per share, and pledged to increase dividends by "more than 10%" for the next three financial years.

"We are pleased with our strong performance in the first half of 2025, delivering double-digit growth across our key metrics in line with the guidance we gave earlier in the year," said chief executive Anil Wadhwani.

"We have reached the inflection point in our capital generation, enabling us to update our capital management programme and increase shareholder returns, which validates our business model and its ability to generate sustainable cash returns."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.